FY2024 Earnings Forecast for ZNTL Issued By Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($2.68) per share for the year, up from their prior forecast of ($3.05). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.76) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($1.01) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.39) EPS and FY2027 earnings at ($3.14) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Several other research analysts have also commented on ZNTL. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday. Finally, Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a research note on Monday, August 12th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.47 on Monday. Zentalis Pharmaceuticals has a 12 month low of $2.66 and a 12 month high of $18.07. The firm has a market capitalization of $247.27 million, a PE ratio of -1.39 and a beta of 1.74. The business’s fifty day moving average price is $3.42 and its 200 day moving average price is $5.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC raised its holdings in Zentalis Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock worth $243,000 after buying an additional 1,274 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares in the last quarter. Kennedy Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the 1st quarter valued at $189,000. Opaleye Management Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter worth about $3,152,000. Finally, SG Americas Securities LLC acquired a new position in Zentalis Pharmaceuticals during the second quarter valued at approximately $58,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.